Leadley, who spent the last 3 years running JeneValve’s clinical program and regulatory strategy, will replace Dr. David Hathaway, who plans to retire, according to a press release. She joined JenaValve from Boston, where she spent 8 years working in its cardiovascular segment, after stints at Advanced Stent Technologies, Pulmonx and Quintiles/The Lewin Group, according to the release.
"Katrin has a wealth of clinical program management experience, and we are confident she will be a great addition to our team," president & CEO Doug Godshall said in prepared remarks. "Her knowledge of cardiovascular device trials and her relationships with many of our international key opinion leaders will enable her to begin making contributions immediately. Katrin has proven experience in identifying new market opportunities, ensuring patient safety and executing clinical development plans and regulatory strategies to achieve product approvals and market introductions of new medical therapies. Katrin will help lead HeartWare through our next stage of clinical and commercial growth, as we advance our ongoing trials, initiate new studies and move toward obtaining regulatory approval of devices in our pipeline.
"HeartWare would like to recognize and express our gratitude toward Dr. David Hathaway who has provided excellent stewardship during the past six years," Godshall added. "Dave has played an integral role in leading us through the clinical process to obtain regulatory approval of the HeartWare ventricular assist system in Europe and as a bridge-to-transplantation therapy in the U.S. HeartWare values Dave’s numerous, meaningful contributions and wishes him well in his retirement, as our organization continues to grow and build upon the foundation he helped us create."
JenaValve last month named ex-AtriCure chief David Drachman as its new CEO.
AngioDynamics eliminates CTO/COO role
AngioDynamics (NSDQ:ANGO) said it’s eliminating the position of chief technology & operations officer, which was held by George Bourne. He is slated to stay on until Sept. 12 and to receive his current salary and benefits for a year after that, AngioDynamics said.
NuVasive names Blackford new CFO
NuVasive Inc. (NSDQ:NUVA) said it named Quentin Blackford to be its new CFO and accounting chief, replacing Michael Lambert, who retired July 31. Lambert is slated to stay on as an advisor through March 15, 2015, NuVasive said.